ScholarIQanswers from OpenAlex & ORCID
Sanjay Popat
ResearcherPublications, citations & collaboration network
Sanjay Popat is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Sanjay Popat have?
ScholarIQindexed works
Sanjay Popat has 833 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Sanjay Popat have?
ScholarIQcitation count
Sanjay Popat has 30,973 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Sanjay Popat?
ScholarIQh-index
Sanjay Popat has an h-index of 62 in OpenAlex.
What is the i10-index of Sanjay Popat?
ScholarIQi10-index
Sanjay Popat has an i10-index of 242 in OpenAlex.
What is the ORCID of Sanjay Popat?
ScholarIQorcid
The ORCID for Sanjay Popat is on the source record.
What is the OpenAlex record for Sanjay Popat?
ScholarIQopenalex
The OpenAlex for Sanjay Popat is on the source record.
What are the most-cited papers on Sanjay Popat?
ScholarIQmost cited works
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Silvia Novello, Fabrice Barlési, Raffaele Califano, Tanja Čufer, Simon Ekman, Matteo Giaj Levra, Keith M. Kerr, Sanjay Popat, Martin Reck, Suresh Senan, G.V. Simo, Johan Vansteenkiste, Solange Peters
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
David Planchard, Sanjay Popat, Keith M. Kerr, Silvia Novello, Egbert F. Smit, Corinne Faivre‐Finn, Tony Mok, Martin Reck, Paul E. Van Schil, Matthew D. Hellmann, Solange Peters
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih‐Hsin Yang, Yi‐Long Wu, Martin Schüler, Martin Sebastian, Sanjay Popat, Nobuyuki Yamamoto, Caicun Zhou, Cheng-Ping Hu, Kenneth J. O’Byrne, Jifeng Feng, Shun Lü, Yunchao Huang, Sarayut Lucien Geater, Kye Young Lee, Chun-Ming Tsai, В. А. Горбунова, Vera Hirsh, Jaafar Bennouna, С. В. Орлов, Tony Mok, Michael Boyer, Wu‐Chou Su, Ki Hyeong Lee, Terufumi Kato, Dan Massey, Mehdi Shahidi, Victoria Zazulina, Lecia V. Sequist
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres, Alexander Drilon, Amélie Lusque, Laurent Mhanna, Alexis B. Cortot, Laura Mezquita, Alesha A. Thai, Céline Mascaux, S. Couraud, Rémi Veillon, Michel M. van den Heuvel, Joel W. Neal, Nir Peled, Martin Früh, Terry L. Ng, V. Gounant, Sanjay Popat, Joachim Diebold, Joshua K. Sabari, Viola W. Zhu, Sacha I. Rothschild, Paolo Bironzo, Alex Martínez‐Martí, Alessandra Curioni‐Fontecedro, Rafael Rosell, Mickaël Lattuca-Truc, Marcel Wiesweg, Benjamin Besse, Benjamin Solomon, Fabrice Barlési, Robert D. Schouten, Heather A. Wakelee, D. Ross Camidge, Gérard Zalcman, Silvia Novello, Sai‐Hong Ignatius Ou, Julie Milia, Oliver Gautschi
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Paul Baas, Arnaud Scherpereel, Anna K. Nowak, Nobukazu Fujimoto, Solange Peters, Anne S. Tsao, Aaron S. Mansfield, Sanjay Popat, Thierry Jahan, Scott Antonia, Youssef Oulkhouir, Yolanda Bautista, Robin Cornelissen, Laurent Greillier, Francesco Grossi, Dariusz M. Kowalski, Jerónimo Rafael Rodríguez‐Cid, Praveen Aanur, Abderrahim Oukessou, Christine Baudelet, Gérard Zalcman